InvestmentJun 25, 2026, 04:32 PM
Taysha Gene Therapies Raises $187.4M in Public Offering
AI Summary
Taysha Gene Therapies, Inc. announced the pricing of an underwritten public offering to issue 32,500,001 shares of common stock and 833,333 pre-funded warrants. The offering price to the public is $6.00 per share and $5.999 per pre-funded warrant. The company expects to receive net proceeds of approximately $187.4 million, or $215.6 million if the underwriters fully exercise their option to purchase additional shares. These funds, combined with existing cash, are anticipated to extend the company's cash runway into the second half of 2028.
Key Highlights
- Offering includes 32,500,001 shares of common stock and 833,333 pre-funded warrants.
- Public offering price is $6.00 per share and $5.999 per pre-funded warrant.
- Underwriters have an option to purchase up to an additional 5,000,000 shares.
- Estimated net proceeds are approximately $187.4 million, or $215.6 million if option exercised.
- The offering is expected to close on June 26, 2026.
- Proceeds, with existing cash, are expected to fund operations into H2 2028.
Price Impact
More from TSHA